Roivant Sciences Ltd. (ROIV) is currently priced at $27.97, showing a price increase of 11.59 cents (0.416%) from the previous close of $27.85. The trading volume is at $1.92 million, representing a 31.44% increase relative to the average.
ROIV's latest quarterly earnings report for Thursday, February 5th, revealed a consensus estimate EPS of -0.27.
The company's cash flow indicates a net change in cash of $241.61 million, with free cash flow at -$191.55 million. Notable figures include stock-based compensation at $105.00 million and common stock issued at $312.8 million.
ROIV reported revenue of $2.00 million, gross profit of $1.30 million, and operating expenses totaling $341.15 million. The net income stands at -$265.89 million, resulting in an EPS and EPS diluted of -38 cents.
Key ratios show a quick ratio of 30.66, gross profit margin of 65%, and price to book ratio of 3.54. Notably, the operating profit margin is -16,966% and the price to sales ratio is 7564.71.
The balance sheet highlights total assets at $5.23 billion, total liabilities at $251.14 million, and net debt of -$1.27 billion.
This real-time financial report provides insights into ROIV's current market performance and financial standing.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.